FindTrial
Sign In

Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation in Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation in Treating Children and Adolescents with Attention-Deficit/Hyperactivity Disorder

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121493
Enrollment
Unknown
Registered
2026-03-31
Start date
2026-04-15
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention-Deficit/Hyperactivity Disorder

Interventions

Trial Group:Repetitive transcranial magnetic stimulation (rTMS): continuous theta burst stimulation (cTBS) applied to the left dorsolateral prefrontal cortex (DLPFC)
stimulation intensity at 80% resting motor threshold (RMT)
stimulation protocol consisted of 3 magnetic pulses at 50Hz forming a pulse burst, repeated at 5Hz (burst duration 0.2s), total of 600 pulses.
Control Group:Repetitive transcranial magnetic stimulation (rTMS): intermittent theta burst stimulation (iTBS) applied to the right dorsolateral prefrontal cortex (DLPFC)
stimulation protocol consisted of 3 magnetic pulses at 50Hz forming a pulse burst, repeated at 5Hz (burst duration 2s, inter-burst interval 8s), total of 1200 pulses.

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 18 Years

Inclusion criteria

Inclusion criteria: 1. Age 80, measured using the Chinese version of the Wechsler Intelligence Scale for Children-IV (WISC-IV); 5. Complete medical records available; 6. Informed consent obtained from both the patient and guardian.

Exclusion criteria

Exclusion criteria: 1. Severe physical illness; 2. Known history of alcohol or drug addiction or abuse; 3. Meeting diagnostic criteria for any mental disorder other than attention deficit hyperactivity disorder (ADHD) or severe uncontrolled illness; 4. Incomplete medical records; 5. Prior transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or other neuromodulation treatments; 6. History of epilepsy, traumatic brain injury, or brain surgery; 7. Presence of metallic implants in the body; 8. Use of antiepileptic drugs or ADHD medications within the past two weeks; 9. Pregnant or lactating women; 10. Other reason deemed by the investigator to make participation in this trial inappropriate.

Design outcomes

Primary

MeasureTime frame
Clinical Response Rate in Attention-Deficit/Hyperactivity;—

Secondary

MeasureTime frame
Therapeutic safety;—

Countries

China

Contacts

Public ContactYin Li

West China Hospital of Sichuan University

yli009@163.com+86 189 8060 6720

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026